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Abstract 
Activation of neutrophils is an important mechanism in pathology of granulomatosis with polyangiitis 
(GPA). In this study, we evaluated if extracellular vesicles (EV) circulating in plasma of GPA patients 
could contribute to this process. 
EV from plasma of GPA patients in active stage of the disease (n=10) and healthy controls (n=10) were 
isolated by ultracentrifugation, characterized by flow cytometry (CD63, CD8) and nanoparticle tracking 
analysis. Targeted oxylipins lipidomics of EV was performed by HPLC-MS2. EV/oxylipins induced 
neutrophil extracellular traps (NETs) were analyzed by confocal microscopy and released dsDNA was 
quantified by PicoGreen fluorescent dye. Reactive oxygen species (ROS) production and neutrophils’ 
EV binding/uptake were evaluated by flow cytometry. Brief priming with granulocyte macrophages-
colony stimulating factor (GM-CSF) was required for EV-mediated ROS production and dsDNA 
release. Priming also increased EV binding/uptake by neutrophils observed, however, only for EV from 
GPA patients. EV from GPA patients had higher concentrations of leukotriene B4 (LTB4) and 5-oxo-
eicosatetraenoic acid (5-oxo-ETE) as compared to EV from healthy controls. Moreover, neutrophils 
stimulated with LTB4 or 5-oxo-ETE produced ROS and released dsDNA in a concentration-dependent 
manner. These results reveal the potential role of EVs containing oxylipins cargo on ROS production 
and NET formation by activated neutrophils. 
 
Keywords: neutrophils, granulomatosis with polyangiitis, extracellular vesicles, neutrophil 
extracellular traps, reactive oxygen species, immunology, inflammation, eicosanoids, leukotrienes 
 
Abbreviations: 
5-HETE - 5-hydroxyeicosatetraenoic acid 
5-oxo-ETE - 5-oxo-eicosatetraenoic acid 
BVAS - Birmingham Vasculitis Activity Score 
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C5a - complement component 5a 
cANCA – anti-neutrophil cytoplasmic antibody, cytoplasmic staining pattern 
CBC - complete blood count 
CRP - C-reactive protein 
dsDNA - double-stranded DNA 
EV – extracellular vesicles 
EV-GPA – extracellular vesicles isolated from the plasma of patients with granulomatosis with 
polyangiitis 
EV-HC – extracellular vesicles isolated from the plasma of healthy controls 
FSC/SSC – forward/side scatter 
GC - glucocorticosteroids 
GM-CSF - granulocyte-macrophage colony-stimulating factor 
GPA – granulomatosis with polyangiitis 
HMGB1 - high mobility group box 1 
LTB4 - leukotriene B4 
LTC4 - leukotriene C4 
MnFI - mean fluorescence intensity 
NET – neutrophil extracellular traps 
NTA - nanoparticle tracking analysis 
PBMC - peripheral blood mononuclear cell 
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PBS -  phosphate-buffered saline 
PLT – blood platelets  
PMN - polymorphonuclear leukocytes 
PPP – platelet poor plasma 
PR3 – proteinase-3  
PR3-ANCA - anti-PR3 antibody 
RFU - relative fluorescence units 
ROS - reactive oxygen species 
TEM - Transmission electron microscopy 
TNF-α – tumor necrosis factor alpha 
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Introduction 
Granulomatosis with polyangiitis (GPA) is an infrequent, autoimmune disease with still 
unknown etiology. Several hypotheses suggest that genetic factors like polymorphisms of proteinase 
inhibitor (alpha- 1 antitrypsin), cytokine genes variants (IL-10) or some HLA genotypes might be 
associated with GPA (1, 2). According to Chapel Hill Consensus Conference (CHC) among primary 
systemic vasculitides, GPA is an anti-neutrophil cytoplasmic antibody (with specificity for proteinase 3 
- PR3-ANCA or cANCA) associated vasculitis affecting small vessels. This definition implies presence 
of circulating cANCA and absence or paucity of immune complex deposits in areas of vasculitis by 
immunohistochemical studies of tissue specimen (3). Among spectrum of cells participating in 
pathophysiology of GPA, neutrophils are playing the most important role. The current paradigm of GPA 
assumes neutrophil activation by IgG anti-PR3 (cANCA), which requires direct recognition of PR3 via 
Fab region of the antibody, and interaction of the Fc part of the antibody with FcγRs on the neutrophil 
surface (4, 5). This causes neutrophil activation, degranulation, generation of reactive oxygen species 
and eventually trans-migration through the endothelial cell layer (6–8). However, a novel mechanisms 
of immune cells activation in pathophysiology of autoimmune disease like GPA can be linked to 
extracellular vesicles (EV).  
Extracellular vesicles are a heterogeneous population of extracellular particles bounded by a 
phospholipid bilayer. They are released by practically all types of cells and can be detected in various 
biological fluids. According to the current nomenclature extracellular vesicles are divided into main 
groups of exosomes and microparticles (9). Exosomes are small (50-150 nm) and are derived from 
endocytic compartment. Microparticles are larger (100-1000 nm) and produced by budding of the 
plasma membrane following a loss of asymmetric distribution of phospholipids and reorganization of 
the cytoskeleton (10). Because distinction between these two population of EV is difficult, classification 
of EV into exosomes or microparticles is rather dogmatic. Some studies are showing that proteins like 
CD63, CD81 or CD9 are mostly present in exosomes likely reflecting their origin (11), whereas these 
markers can also be detected on larger EV (12). It is now recognized that EV are an integral part of the 
intercellular microenvironment and may act as regulators of cell-to-cell communication (10). 
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Extracellular vesicles can deliver proteins to the target cells or may participate in transferring receptors 
between cells. Recently, we observed that tumor-derived EV can induce monocytes/macrophage 
differentiation (13). It is interesting that EV content may differ from the parent cells, moreover different 
stimuli may cause release of EV with different cargo (14, 15). Extracellular vesicles can also contain 
DNA (including mitochondrial DNA), messenger RNA and microRNA but still it is little known about 
EV lipidomics. Several studies on extracellular vesicles lipids showed that EV can contain active 
enzymes linked to lipid metabolism like 12-lipoxygenase, phospholipase A2, C and D or lipid mediators 
like leukotrienes (16–20). The role of extracellular vesicles in GPA and neutrophils activation, 
especially in the context of lipidomics is still unclear. In this study we analyzed potential of plasma 
derived extracellular vesicles of GPA patients to activate neutrophils – focusing on oxylipins cargo of 
EV. We observed that vesicles isolated from GPA patients and not from the healthy controls were able 
to activate neutrophils and form NETs. These data provide insights into the mechanism by which 
extracellular vesicles could activate neutrophils and modulate innate immune response under 
pathological conditions.  
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Materials and methods 
Patients’ recruitment and samples collection  
We enrolled 10 treatment naïve patients in active stage of GPA and 10 healthy sex and age matched 
controls. Disease activity was evaluated using Birmingham Vasculitis Activity Score version 3 
(BVAS>1). Blood samples were collected in the morning, at least 12h after a meal. Basic laboratory 
tests (CBC, CRP, anti-PR3 IgG level) were performed in all participants of the study at the time of 
collection of the peripheral blood. Written informed consent was obtained from all participants of the 
study and the study protocol was accepted by Jagiellonian University Ethic Committee abiding by the 
Declaration of Helsinki principles.  
Neutrophils isolation 
Neutrophils were isolated from healthy donors’ peripheral blood collected into tubes Vacutainer (BD 
Life Sciences, Franklin Lakes, NJ) using Histopaque-1077 gradient centrifugation (Sigma-Aldrich 
Chemical Co, St Louis, USA ) followed by lysis of remaining erythrocytes with ammonium chloride 
buffer. Purity (>98%) of the neutrophils fraction was ascertained by flow cytometry and cells viability 
(>95%) was verified by trypan blue exclusion staining. Immediately after isolation, granulocytes were 
resuspended in X-VIVO 15 medium (Lonza, Basel, Switzerland). 
Extracellular vesicles isolation 
Extracellular vesicles (EV) were isolated from the platelet poor plasma of 10 treatment naïve patents 
with active GPA (BVAS 7-22) and 10 healthy sex and age matched controls by centrifugation. Blood 
samples were taken into Vacutainer tubes with sodium citrate as anticoagulant. After blood collection, 
samples were centrifuged for 10 min at 1450g (no brake) to obtain plasma, upper three-fourths of plasma 
was collected and centrifuged again to obtain platelet poor plasma (PPP, 5000g for 5 min no brake). 
PPP was aliquoted and stored in -80°C. Frozen PPP (2.5 mL) was thawed in water bath for 10 min at 
25°C and centrifuged for 20 min at 3500g to remove any cryoprecipitate. For EV isolation, collected 
supernatant was diluted with PBS (7 mL total sample volume) and passed through 0.8 µm syringe filter. 
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Purification of EV was done by ultracentrifugation in SORVALL WX 80+ ultracentrifuge and T-1270 
fixed angle rotor (Thermo Fisher Scientific, Waltham, MA, USA). EV were pelleted by 
ultracentrifugation (1.5 h, 100000g) were washed with PBS and centrifuged again (1.5 h., 100000g). EV 
pellet was next suspended in 250 µL of filtered PBS, aliquoted and stored in -80 ° C for experiments. 
Extracellular vesicles size distribution and surface markers characterization  
EV number and size distribution was measured using nanoparticle tracking analysis (NTA, NanoSight 
LM10, Malvern Instruments, Amesbury, UK). EV samples were diluted 1:1000 with filterd PBS to 
reduce their number to the linear range of the apparatus, i.e. below 2–10×108/mL. Measurements video 
images were analyzed using NTA 3.1 Build 3.1.46 software (Malvern) captured in script control mode 
(3 videos of 60 s per measurement) using the syringe pump speed 80. A total of 1500 frames were 
examined per sample.  
To rule out any presence of stimulatory endotoxins or anti-PR3 IgG (cANCA) antibodies derived from 
plasma of GPA patients, EV specimens were tested by a colorimetric method detecting bacterial 
endotoxins (Pierce Chromogenic Endotoxin Quant Kit, ThermoFisher Scientific, Waltham, MA, USA), 
and by an indirect immunofluorescence method detecting cANCA (ANCA IFA Granulocyte BIOCHIP 
Mosaic TEST - EUROIMMUN, Germany). 
Evaluation of EV surface markers was performed by flow cytometry as previously described (21, 22). 
Briefly, EV aliquots (10 µL) were resuspended in PBS, mixed with 5 µL of aldehyde/sulfate-latex beads 
(4 μm of diameter, Invitrogen, Carlsbad, CA, USA) and incubated at room temperature for 15 min in 
1.5 mL Eppendorf tube. After incubation, the content was added with 1 mL of 2% BSA in PBS and 
incubated overnight with rotation at 4°C. Bead-coupled EV were pelleted by centrifugation at 2700g for 
5 min, washed with 1 mL of 2% BSA in PBS and centrifuged again. The pellet was resuspended with 
50 μL of PBS and stained with the antibodies anti-CD63 (FITC, BD Biosciences, USA) and anti-CD81 
(PerCP-eFluor 710, ThermoFisher Scientific, Waltham, MA, USA) for 30 min at room temperature.  
Gating of EV-decorated latex beads was on FCS/SSC parameters, thus unbound EV or antibody 
aggregates were excluded from the analysis (Supplemental Figure S1). 
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Targeted oxylipins lipidomics of EV was performed by a high performance liquid chromatography-
tandem mass spectrometry (HPLC-MS/MS). Briefly, samples were enriched with chemically identical 
deuterated standards (Cayman Chemical Co, Ann Arbor, MI, USA), extracted to an organic phase and 
analyzed using multiple reaction monitoring mode (MRM) tandem mass spectrometry (Qtrap 4000, 
Applied Biosytems, CA, USA). Details on the analytical procedure are provided in Supplemental 
Information, Supplemental Tables S1 and S2, and Supplemental Figures S2-S4. 
ROS production 
Generation of reactive oxygen species was measured in granulocytes by flow cytometry using 
dihydrorhodamine 123 (DHR 123). Isolated granulocytes (2×105/225 µl in X-VIVO 15 medium) were 
stained with DHR123 (5 µg/mL, Sigma-Aldrich Chemical Co, St Louis, USA) during 5 min incubation 
in 37°C with gentle shaking (150 rpm). Next, neutrophils were primed with recombinant GM-CSF (25 
ng/ml, R&D Systems, Minneapolis, MN, USA) or left without priming for 15 minutes at 37°C and then 
stimulated with: complement C5a fragment (positive control, 10-8 M), EV from GPA patients or healthy 
controls (25 µL), 5-oxo-ETE or LTB4 (4-400 pg/mL, Cayman Chemical Co, Ann Arbor, MI, USA). 
After 1 h, stimulation was stopped by addition of ice-cold PBS. ROS activity of the samples was 
measured immediately by flow cytometry (BD FACSCanto II) as rhodamine mean fluorescence index 
(MnFI). 
EV binding/uptake by neutrophils 
EV specimens were stained with PKH-76 fluorescent tracker dye (PKH67 Fluorescent Cell Linker Kit, 
Sigma-Aldrich Chemical Co, St Louis, USA) for 5 min in 37°C. Staining reaction was stopped by 
addition of PBS with 1% BSA and removal of unbound dye by 3 cycles of washing/centrifugation using 
Amicon Ultra 0.5 mL centrifugal filters (100K, Merck-Millipore, Billerica, MA, USA). After final 
centrifugation, EV concentrates were restituted to their original volume. 
Presence of PKH 67 labeled EV in granulocytes was measured by flow cytometry (BD FACSCanto II). 
Neutrophils isolated from healthy donors (0.2x106/225 µL) were primed with GM-CSF (25 ng/ml) or 
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left without priming for 15 minutes at 37°C and then incubated with EV (25 µL) for 1 h. After 
stimulation cells, were washed twice by centrifugation and resuspension in PBS and analyzed.  
Quantification of dsDNA release by stimulated human neutrophils  
Isolated human neutrophils (5×105/225 µL in X-VIVO 15 medium) were primed with recombinant GM-
CSF (25 ng/mL, R&D Systems, Minneapolis, MN, USA) or left not primed for 15 min at 37°C and then 
stimulated with the complement C5a fragment (positive control, 10-8 M). EV from GPA patients or 
healthy controls (25 µL), 5-oxo-ETE or LTB4 (4-400 pg/mL, Cayman Chemical Co., Ann Arbor, MI, 
USA) to activate the cells for 1 h. After the incubation, DNase I (EURx, Gdansk, Poland) was added at 
2.5 U/mL concentration for the next 10 min. Reaction was stopped by addition of 2.5 mM EDTA, pH 
8.0 (Sigma-Aldrich Chemical Co, St Louis, USA). Cells were centrifuged at 190g for 5 min at 4°C. 
Content of dsDNA in supernatant was measured using Quant-iT Pico Green dsDNA Assay kit and Qubit 
3 fluorimeter (Thermo Fisher Scientific, Waltham, MA, USA). 
Visualization of neutrophil extracellular traps formation 
Isolated granulocytes were resuspended in X-VIVO 15 medium (2.5x106/mL). Cells were primed with 
25 ng/mL GM-CSF for 20 min on cleaned glass coverslips. Glass pretreatment included washes with 
acetone, ethanol, deionized H2O, baking at 200°C for 1 h. Cells were incubated with 10-8 M C5a or EV 
(25 µL) from GPA patients or healthy controls for 1h at 37ºC in 5% CO2. After stimulation, staining of 
live cells with a cell-permeable fluorescent dye MitoSOX Red (5 µM), was performed. Cells were next 
fixed with 4% paraformaldehyde for 5 min, washed three times in PBS and counterstained with 1 µg/mL 
Hoechst 33342, next mounted in ProLong Gold medium. Slides were examined and images acquired by 
confocal laser scanning microscopy LSM 700 (Carl Zeiss Micro Imaging, Jena, Germany) or DMi8 S 
Platform (Leica Microsytems, Wetzlar, Germany). 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software Inc, San 
Diego, CA). All comparisons were done using one-way analysis of variance (ANOVA) with Tukey’s 
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post hoc test or t-Student test and Mann–Whitney U test. Descriptive statistics were presented as a mean 
± standard deviation or median ± interquartile range. Type I statistical error P<0.05 was considered 
significant. 
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Results  
The study subjects and extracellular vesicles characteristics  
All GPA patients were newly diagnosed and treatment naïve, and were anti-PR3 IgG positive. BVAS 
disease activity score was between 7 and 22 (median = 14). Clinical laboratory tests showed that in 
comparison with healthy controls, GPA patients had elevated number of polymorphonuclear leukocytes 
(PMN) and peripheral blood mononuclear cells (PBMC) (Supplemental Table S3).  
EV isolated from GPA patients (EV-GPA) or healthy controls (EV-HC) were in the same size range and 
concentration (Fig. 1 A and B). Moreover, there were no differences in expression of EV markers. Both 
EV-GPA and EV-HC expressed CD63 and CD81 (Fig. 1C). All EV samples were free of IgG anti-PR3 
antibodies and bacterial endotoxins. 
Extracellular vesicles mediated neutrophils activation 
To evaluate whether plasma derived EV can participate in granulocytes activation observed in GPA, we 
performed experiments in which neutrophils isolated from healthy donors were stimulated with EV. 
Using our preparatory technique, EV 10x concentrated because 250 µL of EV in PBS was obtained from 
2.5 mL of PPP. To mimic EV abundance in plasma, neutrophils were stimulated with 25 µL of EV 
diluted 10-fold in the total cell suspension volume. First, neutrophils were stimulated with EV-GPA or 
EV-HC alone. In result, no differences were noticed between cells stimulated with EV-GPA or EV-HC 
and negative control of medium. For the next experiments, neutrophils were primed with GM-CSF (25 
ng/mL) before addition of EV. Following stimulation with EV, ROS production (Fig. 2A) and release 
of dsDNA (Fig. 2B) were observed. These results were present only if EV-GPA were used. Stimulation 
of primed neutrophils by EV-HC resulted in absence of ROS production or dsDNA release. Moreover, 
direct microscopy showed that DNA released by intact live neutrophils stimulated with EV-GPA was 
likely of mitochondrial origin (Fig. 2C). To analyze how priming can influence EV mediated activation 
of neutrophils, we compared primed or not primed cells incubated with EV stained by fluorescent tracker 
(PKH67). Biding or uptake of EV was evaluated by flow cytometry. We observed that percentage of 
PKH67 positive cells (nautrophils/EV aggregates) was higher for primed cells, however, this was 
evident only for EV-GPA (PKH 67 positive cells: primed vs. unprimed: P<0.05, Fig. 3 and 
Supplemental Figure. S5).  
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Targeted oxylipins lipidomics of extracellular vesicles 
To identify putative stimuli causing neutrophils activation we performed targeted oxylipins analysis of 
EV using HPLC-MS/MS. Out of 14 quantified oxylipins, the lowest concentration in EV was observed 
for LTC4 (EV-GPA: 16.2±8.5 vs. EV-HC: 16.0±8.2 pg/mL, P>0.05, Supplemental Figure S6) and the 
highest for 13,14–dihydro-15-keto PGE2 (EV-GPA: 818±448 vs. EV-HC: 819±448 pg/mL, P>0.05,  
Supplemental Figure S6). Significant differences between EV-GPA and EV-HC were present for LTB4 
(EV-GPA: 470±176 vs. EV-HC: 215±107 pg/mL, P<0.05), 5-oxo-ETE (EV-GPA: 524±279 vs. EV-
HC: 221±81.2 pg/mL, P<0.05) and 5-HETE (EV-GPA: 62.9±31 vs. EV-HC: 28.9±15.7 pg/mL, P<0.05) 
(Fig. 4). 
Oxylipins mediated neutrophils activation 
To confirm functional importance of the oxylipins more abundant in EV-GPA we stimulated neutrophils 
for ROS production and dsDNA release with pure chemical LTB4 and 5-oxo-ETE. 5-HETE, precursor 
of 5-oxo-ETE, had no activity at the measured concentration (Supplemental Figure S7). Stimulation of 
neutrophils with escalated concentrations of LTB4 or 5-oxo-ETE increased ROS production or release 
of dsDNA at the minimal concentration of 4 pg/mL. The peak levels of ROS were observed in cells 
stimulated with 40 pg/mL of LTB4 or 5-oxo-ETE (Fig. 5A). The highest levels of dsDNA release 
occurred after stimulation of granulocytes with 400 pg/mL of LTB4 or 5-oxo-ETE (Fig. 5B). However, 
alike EV-GPA stimulation, neutrophils activation by LTB4 or 5-oxo-ETE required a prior GM-CSF 
priming (Fig. 5C).  
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Discussion  
Circulating EV were already suggested to participate in pathophysiology of autoimmune diseases, 
including GPA. However, most of the previous studies were limited to the descriptive observations. 
Hong et al. showed that neutrophils stimulated with ANCA antibodies can release microparticles 
activating endothelial cells (23). Daniel et al. reported higher plasma level of circulating extracellular 
vesicles in patients with active stage of GPA (24). In contrast to latter observation, we failed to observe 
any differences between concentration of EV isolated from plasma of GPA patients or healthy controls. 
This discrepancy could result from a different methodological approach. Daniel et al. (24) used a low 
speed (15000g) centrifugation as the isolation method, direct analysis with the use of flow cytometry 
but no NTA or TEM analysis. Possibly, authors focused on population of large extracellular vesicles 
like microparticles and apoptotic bodies. Since in the current study ultracentrifugation was used for 
isolation and NTA analysis confirmed enrichment of small EV, this could explain a difference between 
counting of large extracellular vesicles in the previous study, and a population of small exosomes and 
microparticles in the current one. 
Studies on EV are currently very popular research area with a contribution of EV in pathophysiology of 
several disorders confirmed (25–28). However, interactions of EV with granulocytes, especially in 
autoimmune diseases like GPA are poorly investigated. Study of Kuravi et al. showed that platelet 
derived EV can promote adhesion of neutrophils to endothelial cells (16). Dieker et al. reported that 
circulating microparticles isolated from patients with systemic lupus erythematosus participate in 
neutrophil extracellular traps (NETs) formation by LPS stimulated cells (29). Release of dsDNA by 
activated neutrophils was also observed in cells stimulated with small EV (30-150 nm) isolated from 
cell culture supernatants of cancer cells (30). Interestingly, formation of neutrophil extracellular traps 
by activated neutrophils originally was considered one of the neutrophil death pathways, involving the 
rearrangement of nuclear and granular architecture which proceeded from the dissolution of internal 
membranes, followed by chromatin decondensation, cytolysis to formation of nuclear DNA fibers traps 
(31–33). However, we reported that neutrophils can form NETs consisting of mitochondrial DNA in a 
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ROS dependent mechanism and remain viable (34, 35). This observation may shed light on a persistence 
of innate immune response activation in autoimmune disorders. 
Mechanism of activation neutrophils in GPA involves binding of self-reactive anti-PR-3 antibodies, 
which stimulate these cells (4, 5, 36). In the present study stimulation with small EV isolated from the 
plasma of GPA patients led to ROS production and release of dsDNA in GM-CSF primed neutrophils. 
The requirement for the neutrophil priming was met by preincubation with GM-CSF prior to stimulation. 
Higher levels of priming cytokines like TNF-α and GM-CSF were previously documented in GPA by 
us and others, and these observations may explain occurrence of priming effects in vivo (37, 38). 
Moreover, we reported in patients with GPA that level of circulating cell free mitochondrial DNA is 
higher in comparison with healthy controls (39). Taken together, presented results demonstrate that 
neutrophil extracellular traps could be an important mechanism of granulocytes activation in 
pathophysiology of GPA. Since neutrophil is one of the key players in pathophysiology of GPA the 
current findings expand the knowledge supporting this idea.  
Beside increased binding and uptake of EV by primed granulocytes, the cells activation may result from 
oxylipins cargo of EV. This has been shown before in studies on LTB4 or 5-oxo-ETE mediated 
neutrophil aggregation, adherence, calcium mobilization, ROS production or chemotaxis. All these 
effects required neutrophils priming with GM-CSF or TNF-α (40–44). Our result on LTB4 and 5-oxo-
ETE stimulation are in line with these studies. The novel finding of the current study is that EV 
stimulation caused release of dsDNA along with ROS production. This was detectable when primed 
granulocytes were stimulated with LTB4 or 5-oxo-ETE, moreover, only EV-GPA had these stimulatory 
properties containing doubled cargo of LTB4 and 5-oxo-ETE. We also noticed that EV-HC, which 
concentration of LTB4 and 5-oxo-ETE was theoretically sufficient for granulocytes activation did not 
stimulate primed cells to ROS production or dsDNA release. This could be explained by several factors. 
First, due to a complexity of EV cargo, EV-HC can contain molecules suppressing neutrophil activation. 
Anti-inflammatory potential of EV has been reported for neutrophil-derived microparticles isolated from 
healthy donors or rheumatoid arthritis patients (48, 49). Second, EV-HC might be deficient in some 
target molecules crucial for internalization by granulocytes. Duchez et al. reported that active 12-
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lipoxygenase was essential for neutrophils internalization of platelet derived EV (45), while studies of 
Maugeri et al. showed that this process required presence of HMGB1 which was absent in microparticles 
isolated from healthy donors (46, 47). In the current study we did not analyzed any potential proteins 
involved in EV uptake by granulocytes. However, we observed that priming of neutrophils with GM-
CSF resulted with increased EV biding/uptake only for EV-GPA, explaining lack of EV-mediated 
neutrophils activation when EV-HC were used. However, only experiments using antagonists of 
receptors BLT1 or 2 and OXER1 could provide additional evidence to confirm the specific role of these 
two oxylipins. 
Mechanism of release and intracellular origin of small EV is difficult to study ex-vivo, thus a cellular 
source of plasma circulating EV remains uncertain. In contrast to large microparticles, classical lineage 
membrane markers like CD11b for granulocytes or CD42a for platelets can’t be used (50). However, 
some previous studies provided information on the origin of EV by their oxylipins content (51, 52). 
Duchez et al. reported that in platelet derived exosomes the main arachidonic acid metabolite is 12-
HETE (45). In our study high levels of LTB4 and 5-oxo-ETE were detected, produced by a 5-
lipoxygenase (ALOX-5) positive granulocytes. 5-lipoxygenase is also expressed in monocytes, 
macrophages and dendritic cells (53–55). Study by Esser et al. suggested LTC4 as the main eicosanoid 
in exosomes from macrophages and dendritic cells (17), whereas more recently Majumdar et al. reported 
that during chemotaxis neutrophils release LTB4 enriched extracellular vesicles (56). Interestingly 
enough, 5-oxo-ETE is the major metabolite of 5-HETE formed during ROS production in neutrophils 
(57). We published previously on increased biosynthesis of these two mediators in the asthmatics 
following positive challenge with a house dust mite allergen, which correlated with the late phase of 
allergic inflammation (58). Taken together, it is highly plausible that granulocytes are the main source 
of small EV in patients with GPA. We acknowledge this study lacked appropriate methods to evaluate 
ex-vivo the mechanism of EV formation, and this will require future investigations. 
In conclusions, we described a novel observation that primed neutrophils can be stimulated by 
circulating EV-GPA to produce ROS and release dsDNA. Moreover, by a targeted lipidomics we 
demonstrated that pro-inflammatory oxylipins of 5-lipoxygenase pathway had increased concentration 
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in EV-GPA, and their activity could be mimicked by chemically pure LTB4 or 5-oxo-ETE. The current 
results also confirm that release of dsDNA by NET formation is important mechanism of neutrophils 
activation in pathophysiology of GPA.  
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Figure 1. Panel A - Concentration and size distribution of plasma derived extracellular vesicles 
(EV). Results are presented as mean ± SD. Panel B and C - Representative histograms of size 
distribution (panel B) and CD63/CD81 expression (panel C) of EV. Left panel – EV isolated 
from GPA patient, right panel – EV isolated from healthy donor. Panel C –light gray - isotype 
control, - dark gray CD63 or CD81. 
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Fig. 2. Extracellular vesicle isolated from GPA patients activates human neutrophils. 
Neutrophils were isolated from the blood of healthy donors (n=6) and stimulated with C5a 
(positive control) or EV-GPA (n=10) and healthy controls (EV-HC, n=10). In each experiment 
cells were primed (GM-CSF, 25 ng/ml) or left not primed for 15 min before stimulation in 
parallel experiments with EV-GPA or EV-HC. Each EV sample was tested with neutrophils 
from two different donors. (A) Total ROS production by activated neutrophils was measured 
by flow cytometry. (B) Quantification of dsDNA in supernatants of activated neutrophils was 
performed using PicoGreen fluorescent dye. (C) Confocal microscopy. Representative images 
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of extracellular DNA release following short-term stimulation (total 45 min) of human 
neutrophils with the simuli. Cells were labeled with 5 µM MitoSOX Red to stain the 
extracellular DNA and cell nucleus was stained with 1 µg/ml Hoechst 33342. Scale bars are 10 
µm. The images were acquired by confocal scanning microscope. GPA-EV - extracellular 
vesicles isolated from plasma of patients with granulomatosis with polyangiitis, HC-EV - 
extracellular vesicles isolated from plasma of healthy donors. Results are presented as mean ± 
SD of MnFI or RFU and were tested with the use of ANOVA with Tukey post-hoc test. *P<0.05 
compared with non-stimulated control 
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Figure 3. Binding of EV to primed and unprimed neutrophils. Neutrophils isolated from the 
blood of healthy donors (n=6) were primed with GM-CSF or left not primed for 15 minutes at 
37°C, next added with PKH 67-stained EV (isolated from GPA patients or healthy controls) for 
1h. Results are presented as median ± interquartile range of PKH67 positive cells and were 
tested with the use of ANOVA with Tukey post-hoc test. A control of not primed neutrophils 
added EV not stained with PKH 67 was used (for gating strategy see Supplemental Figure S5). 
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Figure 4.Extracellular vesicles (EV) levels of leukotriene B4 (LTB4), 5-hydroxyeicosatetraenoic 
acid (5-HETE) and 5-oxo-eicosatetraenoic acid (5-oxo-ETE).. EV were isolated from plasma of 
patients with granulomatosis with polyangiitis (GPA, n=10) and healthy controls (HC, n=10) 
and targeted oxylipins lipidomics of EV was performed by a high performance liquid 
chromatography-tandem mass spectrometry. Results are presented as mean ± SD. Differences 
between studied groups were tested with the use of t-Student test. 
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Figure 5. ROS production (panel A) and dsDNA release (panel B and C) by human neutrophils 
primed with GM-CSF and stimulated with LTB4 or 5-oxo-ETE. (A and B) Neutrophils isolated 
from the blood of healthy donors (n=6) were primed with GM-CSF (25 ng/ml) or left not primed 
for 15 minutes at 37°C, and next stimulated with serial dilutions of 5-oxo-ETE or LTB4. 
Concentration of 40 pg/ml for 5-oxo-ETE or LTB4 is representative for the mean concentration 
of both eicosanoids in experiments in which cells were stimulated with plasma derived EV 
isolated from patients with GPA. (C) Fluorescence microscopy. Representative images of 
extracellular DNA release following short-term stimulation (total 45 min) of human neutrophils 
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with the indicated stimuli. Cells were labeled with 5 µM MitoSOX Red to stain the extracellular 
DNA and nucleus stained with 1 µg/ml Hoechst 33342; Scale bars are 10 µm. The images were 
acquired by fluorescence microscope (DMi8, Leica). Results are presented as mean±SD and 
were tested with the use of ANOVA and Tukey post-hoc test. *P<0.05 compared with non-
stimulated control. 
 
